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Inflammation and neurodegeneration coexist in many acute damage and chronic CNS disorders (e.g., stroke, Alzheimer’s disease,
Parkinson’s disease). A well characterized animal model of brain damage involves administration of kainic acid, which causes limbic
seizure activity and subsequent neuronal death, especially in the CA1 and CA3 pyramidal cells and interneurons in the hilus of the
hippocampus. Our previous work demonstrated a potent anti-inflammatory and neuroprotective effect of two thiadiazolidinones com-
pounds, NP00111 (2,4-dibenzyl-[1,2,4]thiadiazolidine-3,5-dione) and NP01138 (2-ethyl-4-phenyl-[1,2,4]thiadiazolidine-3,5-dione), in
primary cultures of cortical neurons, astrocytes, and microglia. Here, we show that injection of NP031112, a more potent thiadiazolidi-
none derivative, into the rat hippocampus dramatically reduces kainic acid-induced inflammation, as measured by edema formation
using T2-weighted magnetic resonance imaging and glial activation and has a neuroprotective effect in the damaged areas of the hip-
pocampus. Last,NP031112-inducedneuroprotection, both in vitroand in vivo, was substantially attenuatedby cotreatmentwithGW9662
(2-chloro-5-nitrobenzanilide), a known antagonist of the nuclear receptor peroxisome proliferator-activated receptor, suggesting that
the effects of NP031112 can be mediated through activation of this receptor. As such, these findings identify NP031112 as a potential
therapeutic agent for the treatment of neurodegenerative disorders.
Key words: excitotoxicity; neurodegenerative diseases; neuroinflammation; neuroprotection; peroxisome proliferator-activated recep-
tor; thiadiazolidinones
Introduction
Excitotoxic brain damage is considered one of the major mecha-
nisms bywhich neurons die in the adult CNS (Choi, 1988; Lipton
and Nicotera, 1998). Studies using kainic acid (KA), an analog of
glutamate, have provided major contributions to the under-
standing of neuronal cell death caused by excitotoxicity. Admin-
istration of KA in rats is known to induce a sequence of altered
behavioral events characterized by epileptiform seizures (Ben-
Ari et al., 1980; Sperk, 1994), which are followed by neurodegen-
eration in specific brain regions, such as the hippocampus, piri-
form cortex, thalamus, and amygdala. In the hippocampus, the
CA3 pyramidal cells and interneurons in the hilus of the dentate
gyrus are the most vulnerable, followed by CA1 pyramidal cells
(Coyle, 1983; Sperk et al., 1985; Tauck and Nadler, 1985). An
essential event in excitotoxicity is the direct and constant activa-
tion by KA of specific glutamate receptors, which results in neu-
ronal cell death (Choi, 1988; Doble, 1999; Wang et al., 2005). In
addition, glial cells, as mediators of the inflammatory response,
also play an important role in the course of KA-induced hip-
pocampal neurodegeneration. Activated astrocytes and micro-
glial cells proliferate and increase the expression of genes impli-
cated in the production of nitric oxide and cytokines. These
agents, when released from activated glia, can contribute notice-
ably to the expansion of brain injury and the delayed loss of
neurons (Barone and Feuerstein, 1999; del Zoppo et al., 2000).
Neuroprotection involves the use of agents to prevent disease
or injury of the nervous system by inhibiting one or more events
leading to neuronal death. Brain injury, as a consequence of vas-
cular or traumatic accidents or neurodegenerative diseases, is a
common event, and therefore, neuroprotection has emerged as
an increasingly important segment of the biopharmaceutical
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market over the last years, representing a major source of un-
tapped potential for development of new therapeutic products
and strategies. Formerly, most therapy for neurological disorders
was directed at symptoms; however, as the understanding of the
molecular basis of neurological disease and injury increases, op-
portunities for new approaches appear. The peroxisome
proliferator-activated receptor  (PPAR) has recently emerged
as a therapeutic target for neuroprotection (Petrova et al., 1999;
Bernardo et al., 2000; Landreth and Heneka, 2001; Diab et al.,
2002; Townsend and Pratico, 2005). PPAR ligands, including
the antidiabetic thiazolidinediones (TZDs), nonsteroidal anti-
inflammatory drugs (NSAIDs), such as indomethacin, and the
prostaglandin derivative 15-deoxy--12,14-prostaglandin J2, have
been implicated in the anti-inflammatory process in diverse tis-
sues, including the brain (Ricote et al., 1999; Kielian and Drew,
2003). In line with these results, we have recently shown that two
thiadiazolidinone (TDZD) compounds, NP00111 (2,4-dibenzyl-
[1,2,4]thiadiazolidine-3,5-dione) and NP01138 (2-ethyl-4-
phenyl-[1,2,4]thiadiazolidine-3,5-dione), inhibited the activa-
tion of astrocytes and microglial cells and were neuroprotective
in vitro through a mechanism apparently involving PPAR acti-
vation (Luna-Medina et al., 2005), suggesting that TDZDs may
act as anti-inflammatory and neuroprotective agents in the CNS.
In the present study, we demonstrate that NP031112, another
TDZD compound, which is presently being developed for the
treatment of Alzheimer’s disease, is a potent anti-inflammatory
and neuroprotective agent against KA-induced in vivo excitotox-
icity. TDZD compounds have been shown to be non-ATP com-
petitive inhibitors of glycogen synthase kinase 3 (GSK-3)
(Martinez et al., 2002a,b). It has also been shown that inactivation
of GSK-3 protects against KA-induced neurotoxicity in vivo
(Goodenough et al., 2004), and therefore this pathway could be
involved in the NP031112 response to the excitotoxin in vivo.
However, our results suggest that NP031112 may act as well
through its ability to activate the PPAR nuclear receptor.
Materials andMethods
Cell culture, transfection, and treatment. Rat primary astrocytes, micro-
glia, and neurons were harvested and cultured as described previously
(Luna-Medina et al., 2005). The purity of the cultures was 95%, as
determined by immunofluorescence analysis using anti-cd11b (OX-42)
to detect microglial cells, glial fibrillary acidic protein (GFAP) to identify
astrocytes, and anti-microtubule-associated protein 2 (MAP2) to iden-
tify neurons. NP031112 (2.5 M) was added to the culture medium of
astrocytes andmicroglia 1 h before exposure to glutamate (500M), cells
were incubated for 24 h before tissue culture medium was collected, and
the cells were evaluated for tumor necrosis factor- (TNF-) and cyclo-
oxygenase type 2 (COX-2) expression. For transient transfection exper-
iments, primary cultures of astrocytes were transfected with the reporter
plasmid pPPRE-tk-luc, containing three PPAR consensus binding sites
upstream of a minimal promoter using Transfast (Promega, Madison,
WI) according to the manufacturer’s guidelines. Typically, cells received
0.2 g of luciferase reporter plasmid and were harvested 24 h after treat-
ment with different concentrations of NP031112 for determination of
luciferase and -galactosidase (to determine transfection efficiency) ac-
tivities. Each transient transfection experimentwas repeated at least three
times in triplicate.
Antibodies. Mouse monoclonal antibodies to MAP2 and GFAP were
from Sigma (St. Louis, MO). Mouse OX-42 and anti-neuN monoclonal
antibodies were purchased from Serotec (Duseldorf, Germany), Milli-
pore (Bedford, MA), respectively. Polyclonal anti-TNF- and anti-
COX-2 antibodies were from Santa Cruz Biotechnology (Santa Cruz,
CA).
Immunocytochemistry.At the end of the treatment period, the cultures,
grown on glass coverslips in 24-well cell culture plates, were washed with
PBS and fixed for 30 min with 4% paraformaldehyde at 25°C and per-
meabilized with 0.1% Triton X-100 for 30 min at 37°C. After 1 h incu-
bation with the corresponding primary antibody, cells were washed with
PBS and incubated with an Alexa-labeled secondary antibody (Invitro-
gen, San Diego, CA) for 45 min at 37°C. Images were acquired using a
Radiance 2100 confocal microscope (Bio-Rad, Hercules, CA), with a 350
nm diode laser to excite DAPI (4,6,diamidino-2-phenylindole) and 647
nm laser line to excite Alexa 647. Confocal microscope settings were
adjusted to produce the optimum signal-to-noise ratio. To compare flu-
orescence signals from different preparations, settings were fixed for all
samples within the same analysis. Fluorescence analysis was performed
using LaserPix software (Bio-Rad). A quantitative analysis of labeled cells
was undertaken using the image analySIS software (Soft Imaging System,
Mu¨nster, Germany) and normalized to total nuclei. Areas to be counted
were traced at high power (400), and at least four different counting
fields were selected at random per culture.
Measurement of apoptosis. To calculate the extent of apoptotic cell
death, cortical neuronal cultures were treated or not with NP031112 and
incubatedwith glutamate (100M), and phosphatydilserine exposure on
the surface of apoptotic cells was detected by confocal microscopy after
staining with Annexin V-FITC (Bender MedSystems, Vienna, Austria).
Neuronal cell death was assessed by counting the percentage of Annexin-
V-positive cells in four independent high-magnification (200) fields
per culture, as described above.
KA administration.AdultmaleWistar rats (8–12 weeks old) were used
in this study. Adequatemeasureswere taken tominimize pain or discom-
fort of animals. Experiments were performed in accordance with the
European Communities Council, directive 86/609/EEC. Rats (n 5 per
group) were anesthetized by intraperitoneal injection of ketamine (60
mg/kg) and Domtor (5 g/kg) and placed into a stereotaxic apparatus
(David Kopf Instruments, Tujunga, CA). KA (1 g in 2.5 l PBS) alone
or in combination with NP031112 (2 ng in 2.5 l PBS) was injected into
the hippocampus [coordinates from bregma: posterior, 3.0 mm; lat-
eral, 2.0 mm; depth, 3.5 mm; according to the atlas of Paxinos and
Watson (1998)]. Control animals of the same age were injected with
vehicle. Two groups of animals also received 0.7g of the PPAR antag-
onist GW9662 (2-chloro-5-nitrobenzanilide), either alone or in combi-
nation with KA. Each injection was performed for 2.5 min using a
micropump (KD Scientific, Holliston, MA). The amounts of NP031112
and GW9662 used were calculated based on the in vitro results to reach
active concentrations within the hippocampus. Lithium chloride (LiCl),
a potent inhibitor of GSK-3 activity, was administered (40mg/kg/d) by
intraperitoneal injection to a further two groups of animals, either alone
or in combination with KA. The rats were then housed individually to
recover.
Seizures were induced by intraperitoneal administration of rats with
KA (10 mg/kg) in PBS. Control animals received saline only. Behavioral
analysis was monitored for a period of 3 h by trained observers blind to
the treatment of the rats. The convulsive behavior was classified accord-
ing to Racine (1972) and Sperk et al. (1985) as follows: stage 0, no chang-
es; stage 0.5, wet dog shakes (WDS); stage 1, mouth and facial move-
ments; stage 2, head nodding; stage 3, forelimbs clonus; stage 4, rearing;
stage 5, rearing and falling; stage 6, death. Status epilepticus (SE) was
defined as continuous behavioral seizure activity (stage 5) for 5 min.
The number of WDS before SE was also examined. In trials using
NP031112, the TDZD was administered intragastrically (50 mg/kg) 1 h
before KA injection.
Magnetic resonance imaging. Magnetic resonance imaging (MRI) was
performed using a 7.0 tesla horizontal bore (16 cm) magnet interfaced
with a Bruker Pharmascan console (Bruker Medical, Ettlingen, Ger-
many). Rat brain MRI was performed with a 90 mm gradient insert and
a concentrical 38 mm birdcage resonator, using Paravision version 3.1
software (Bruker Medical), as implemented in a Hewlett-Packard (Palo
Alto, CA) Linux platform.MRI examinations used adultmaleWistar rats
(n 5; 250 g) anesthetized through a plastic mask with 2% isoflurane in
99.9% O2. Animals were allowed to breath spontaneously during the
experiment and were placed in a heated cradle to maintain the core body
temperature at37°C. The physiological state of the animal was moni-
tored throughoutMRI acquisition through the respiratory rate and body
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temperature, as monitored by a rectal probe. T2-weighted spin-echo im-
ages were acquired at 1, 2, 3, and 9 d after KA injection with a rapid
acquisition with relaxation enhancement (Hennig et al., 1986) sequence
in axial orientations [repetition time (TR), 2500 ms; echo time (TE), 60
ms; averages, 3; field of view, 2.65 cm; acquisitionmatrix, 256 256; slice
thickness, 1.50 mm; number of slices, 15]. The in vivo spectroscopy pro-
tocol acquired two 4 4 4 mm voxels in the hippocampal area, using
a point-resolved spatially spectroscopy (Bottomley, 1987) protocol,
combined with VAPOR water suppression (Tkac et al., 1999) (TR, 3000
ms; TE, 35 ms; averages, 128). The lesion area was calculated from T2-
weighted images using image analySIS software (Soft Imaging System).
Lesion volume was estimated from the summation of areas of hyperin-
tensity on each slice, multiplied by slice thickness. Average lesion volume
was calculated for each treatment.
Immunohistochemistry. At different times after stereotaxic injection,
the animals were anesthetized and perfused transcardially with 4% para-
formaldehyde solution. The brains were removed, postfixed in the same
solution at 4°C overnight, cryoprotected in the paraformaldehyde solu-
tion containing 30% sucrose, frozen, and 30 m coronal sections were
obtained in a cryostat. Free-floating sections were processed for cresyl
violet (Nissl stain) or immunohistochemistry using the diaminobenzi-
dine method or double-immunofluorescence analysis. For the diamino-
benzidine method, floating sections were immersed for 15 min in 3%
H2O2 to inactivate endogenous peroxidase, and then blocked for 2 h at
room temperature (RT) in 5% normal goat serum (NGS; Vector Labo-
ratories Burlingame, CA) in PBS, containing 4% bovine serum albumin,
0.1 M lysine, and 0.1% Triton X-100. Afterward, the sections were incu-
bated overnightwith the corresponding primary antibodies. After several
rinses, sections were incubated for 1 h with a biotinylated secondary
antibody. Finally, the sectionswere processed after the avidin-biotin pro-
tocol (Vectastain ABC kit; Vector Laboratories). Tissues were mounted
onto gelatin-coated slides and were let to dry. Finally, the slides were
dehydrated, cleared in xylene, and mounted with DePeX (Serva, Heidel-
berg, Germany). The slides were examined with a Zeiss (Oberkochen,
Germany) Axiophot microscope, equipped with an Olympus Optical
(Tokyo, Japan) DP-50 digital camera, and a Leica (Nussloch, Germany)
MZ6 modular stereomicroscope. Neuronal integrity was assessed by
counting the percentage of Nissl-positive cells in the CA3 region of the
hippocampus in five independent well defined high-magnification
(400) fields per animal using a computer-assisted image analySIS soft-
ware (Soft Imaging System). The extent ofmicrogliosis was quantified by
counting the number of OX-42-positive cells in five independent well
defined high-magnification (400) fields per animal, as described above.
To evaluate astrogliosis, two different parameters were quantified: num-
ber of activated cells, based on the calculation of highly immunostained
cell body profiles, and immunosignal intensity, based on the measure-
ment of optical density. Individual cell bodies were manually traced, and
their mean staining intensity was normalized against the background of
the respective section, defined as tissue devoid of specific immunostain-
ing. The procedure resulted in arbitrary values on a scale from 1 (back-
ground staining) to 256.
For the double-immunofluorescence, the protocol was similar to the
one described above with some modifications. Briefly, the floating sec-
tions were blocked for 1 h in PBS containing 0.25%Triton X-100 and 3%
NGS and incubated overnight with the corresponding primary antibod-
ies. Then, AlexaFluor 647 and AlexaFluor 488 secondary antibodies were
added for 1 h at RT. Finally, the tissue wasmounted withmowiol and the
sections were examined as described for immunocytochemistry. The se-
quential mode was used to acquire fluorescence images to avoid any
interference from overlapping fluorescence. The images were obtained
using a series of 0.5-m (depth)-spaced cell fluorescent slices (z-axis).
Statistical determinations. The data shown are the means  SD of at
least three independent experiments. Statistical comparisons for signifi-
cance between cells with different treatments were performed using the
Student’s test, with p  0.05. ANOVA was used to analyze the data of
Figures 2–6.
Results
NP031112 inhibits glutamate-induced glial activation and
protects cortical neurons from cell death in vitro
We first analyzed whether NP031112 affected the glutamate-
induced expression of TNF- and COX-2, two well known
proinflammatory agents, in primary glial cultures. As shown in
Figure 1a, incubation of both astrocyte and microglial cultures
with NP031112 completely abrogated the induction of TNF-
andCOX-2 expression after glutamate treatment. These effects of
NP031112 were not caused by a loss of cell viability, because the
24 h exposure of astrocyte and microglial cells to this TDZD did
not modify cell viability (data not shown).
TDZD compounds were originally described as GSK-3 in-
hibitors (Martinez et al., 2002a,b) and, more recently, we have
shown that their effects on neural cells in vitro seems to be medi-
ated through activation of the PPAR nuclear receptor (Luna-
Medina et al., 2005). Therefore, we next tested whether LiCl (an
inhibitor of GSK-3) mimicked the effect of NP031112 and
whether the specific PPAR antagonist GW9662 impaired the
action of this TDZD. As shown in Figure 1a, treatment of astro-
cyte and microglial cultures with LiCl did not have a major effect
on the increase in TNF- andCOX-2 expression elicited by treat-
ment with glutamate. On the contrary, GW9662 significantly in-
hibited the blocking effects of NP031112 on TNF- and COX-2
expression after glutamate treatment of glial cultures, suggesting
an involvement of PPAR in the protective effects of NP031112
against the response of glial cultures to glutamate treatment.
In addition to its blocking effect in glial activation after an
excitotoxic insult triggered by glutamate treatment, NP031112
was also able to exert a potent neuroprotective effect on cortical
neurons from glutamate-induced excitotoxicity (Fig. 1b). Treat-
ment of neuronal cultures with NP031112 resulted in a signifi-
cant reduction in the number of Annexin-V-positive cells com-
pared with untreated cells. As observed with glial cultures, the
PPAR antagonist GW9662 attenuated the neuroprotective ef-
fects of NP031112, whereas the GSK-3 inhibitor LiCl did not
have any effect on glutamate-induced cell death or inflammatory
response.
To further analyze the possible involvement of PPAR on
NP031112 actions, we next examined whether this compound
could activate a reporter construct containing three consensus
PPAR response elements (PPRE-tk-luc) in primary cultures of
astrocytes. Figure 1c shows a dose–response of the induction by
NP031112 of PPRE-tk-luc reporter construct. Half-maximal
stimulation was reached at 1.16 M and maximal stimulation
(23-fold) at 25MNP031112. No bigger induction was observed
with higher doses of the compound. These results further suggest
that NP031112 can be acting through a PPAR-dependent
mechanism.
Neuroprotective role of NP031112 after excitotoxic
brain injury
Given the in vitro anti-inflammatory and neuroprotective effects
described above, we then assessed the efficacy of NP031112 in an
established focal excitotoxic model in vivo. To this end, adult rats
received intrahippocampal injections of vehicle, KA, or KA plus
NP031112 and were killed at different times after injection. Be-
cause brain edema is a common pathological trait of brain injury,
we first used MRI to determine the neuroprotective efficacy of
NP031112 in vivo. T2-weighted MRI allows the visualization
of areas of brain edema as hyperintense regions. Indeed, areas of
hyperintensity in T2-weighted images, reflecting cerebral edema
or neurodegeneration, were found in the ipsilateral hemisphere
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of KA-injected rats 24 h after KA injection,
their hyperintensity becoming further en-
hanced after 2, 3, and 9 d (Fig. 2a). Coin-
jection of NP031112 resulted in a signifi-
cant decrease in the hyperintensity of T2-
weighted images, compared with the
untreated KA-injected animals. Lesion
volume was significantly reduced at all of
the times studied after KA injection in the
NP031112-treated group. By day 9, the
damage in NP031112-treated animals was
almost completely absent (98% reduction
relative to KA-injected animals) (Fig. 2b).
Single-voxel proton nuclear magnetic res-
onance spectra from the hippocampal re-
gion of vehicle-, KA, and KA plus
NP031112-injected animals are shown in
Figure 2c. The spectral patterns between
the vehicle- and the KA-injected rats were
considerably different (Fig. 2d). In partic-
ular, KA administration was associated
with a progressive and significant decrease
of N-acetyl-aspartate (NAA)/creatine ra-
tio and an increase in lactate/creatine ratio
in the ipsilateral hippocampus, suggesting
neuronal loss. On the contrary, the spectra
observed in NP031112-injected rats were
very similar to those found in vehicle-
treated animals. These findings indicate
that NP031112 protects the brain against
KA-induced damage.
The MRI results were further con-
firmed by histological analysis of the hip-
pocampus. Nissl staining was used to eval-
uate the extent of neuronal loss in the
hippocampus of vehicle-, KA-, and KA
plus NP031112-injected rats. A significant
preservation of hippocampal cells was
found in NP031112-injected rats com-
pared with abundant neuronal loss in the
CA1, CA3, and hilus after injection with
KA (Fig. 3a). Three days after the injec-
tion, cell loss in CA1 and CA3 layers was
apparent in both groups of animals, al-
though it becamemore intense in the KA-
injected group. Remarkably, by 9 d, both
CA1 and CA3 regions of the hippocampus
of NP031112-injected rats were almost
completely normal, compared with KA-
injected cells, which still presented a sig-
nificant neuronal loss and a disorganiza-
tion of both regions of the hippocampus.
Figure 1. Effects of NP031112 on excitotoxic neural injury in vitro. a, Rat primary astrocyte or microglial cultures were treated
for 24 hwith glutamate (500M) in the absence or presence of NP031112 (2.5M), and the expression of TNF- and COX-2 was
evaluated by immunofluorescence analysis and confocal microscopy using specific antibodies, as described in Materials and
Methods. Somecultureswerepreincubated1hwith30MGW9662before theadditionofNP031112orwith20mMLiCl before the
addition of glutamate. Representative results of three different experiments are shown. Scale bars, 10m. Nuclei were counter-
stained with DAPI (blue). b, Rat primary neuronal cultures were treated for 24 h with glutamate (100 M) in the absence or
presence of NP031112 (2.5M). Some cultures were preincubated 1 h with 30M GW9662 before the addition of NP031112 or
with 20mMLiCl before the additionof glutamate, andapoptosiswas assessedbyAnnexin-V-FITC staining as described inMaterials
andMethods. Representative confocal images of three independent experiments are shown. Scale bars, 10m. Values ina andb
represent the mean SD from three different experiments and five independent fields ( 50 cells/field) per culture. ***p
0.001. c, Activation of a PPRE (peroxisome proliferator response element) reporter gene by NP031112. Rat primary astrocytes
4
were transfected with 0.2 g of the PPRE-tk-luc reporter
plasmid, cells were harvested 24 h after treatment with
NP031112 at the indicated concentrations, and luciferase ac-
tivity of cell lysates was determined. Data are expressed rela-
tive to the basal values and represent the mean SD lucif-
erase activity determined in triplicate in three independent
experiments. **p 0.01; ***p 0.001, versus control non-
treated cultures. GLUT,Glutamate; B, basal; GW,GW9662;NP,
NP031112.
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Quantitative studies (Fig. 3b) showed a decrease of 85, 96, and
94%, compared with the vehicle-injected rats, in the number of
neurons in the CA3 subfield of the hippocampus 1, 3, and 9 d,
respectively, after KA injection. In contrast, in the NP031112-
treated group, only a moderate decrease (47%) in cell number
was observed 3 d after KA injection. These results extend the
observations made in vitro and suggest that treatment of KA-
injected animals with NP031112 results in an almost complete
recovery of the regions more affected by the injury.
One of the events that take place in the hippocampus after
excitotoxic injury is the sequential activation of microglia and
astroglia. Concerning astrogliosis, resting astrocytes were distrib-
uted mostly in the stratum lacunosum-moleculare layer of the
hippocampus (LMol) of vehicle-injected animals (Fig. 4a).
Twenty-four hours after KA injection, the highest GFAP immu-
noreactive signal intensity was not only observed in the LMol but
also in the hilus of the dentate gyrus (data not shown). Nine days
after injury, a dramatic increased in GFAP immunoreactivity was
detected in all regions of the hippocampus (Fig. 4a). This strong
astrogliosis was completely absent in the animals treated with
NP031112, and the pattern of GFAP immunostaining in these
animals was indistinguishable from that of control animals.
Figure 2. Effect of NP031112 on KA-induced brain edema as detected by MRI. T2-weighted imaging was performed at 7 tesla as described in Materials and Methods at different times after KA
injection. a, Representative coronal images of rat brain injectedwith vehicle (top), KA (middle), and KA plus NP031112 (bottom). Hyperintensity areas in T2-weightedMRIs reveal regions of edema
after KA injection. Hyperintense areas were reduced in the NP031112-treated rats compared with the KA-injected rats, demonstrating a decrease in the injured area. No hyperintensity was found
in the vehicle-injected rats. Arrows indicate the injection site. An anatomic diagram (Paxinos, 1998) showing (arrow) the precise localization of themicroinjection in the rat hippocampus is shown.
b, Quantitative analysis of total lesion volumes of KA- and KA plus NP031112-injected rats. The volume of the edemas was significantly lower in NP031112-treated rats, compared with KA-treated
group at all of the times studied. Values represent the mean SD from five different animals and five independent sections per animal. ***p 0.001. c, Representative point-resolved spatially
spectra acquired fromthehippocampal region (whitebox)with resonances fromNAA, lactate (Lac), and creatine (Cr) 9dafter treatment.d, Time courseof variationofNAAor lactate values (mean
SD) in the ipsilateral hemisphere of control-, KA-, and KA plus NP031112-treated animals during 9 d, normalized to the creatine peak. V, Vehicle; NP, NP031112. *p 0.05; **p 0.01; ***p
0.001, versus vehicle-injected animals at each time point.
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Quantification of the data revealed a 6.7- and 2.2-fold decrease in
both the number of strongly GFAP astrocytes and staining in-
tensity, respectively, in theNP031112-treated animals, compared
with the KA-injected group (Fig. 4b). Microglial activation in the
contralateral hippocampus of kainic-injected rats, as well as in
the hippocampus of vehicle-injected animals, was at almost un-
detectable levels in all regions of the hippocampus (Fig. 4c). After
KA injection, numerous reactive microglial cells appeared in the
ipsilateral part of all regions of the hippocampus. KA treatment
resulted in morphological changes in microglial cells, which in-
cluded swelling of the cell somas and thickening and retraction of
the cell processes, two characteristic features of reactivemicroglia
(Jorgensen et al., 1993; Ladeby et al.,
2005). Coadministration of NP031112 to-
getherwithKAcompletely blockedmicro-
glial activation. Quantitative analysis of
OX-42 cells from KA- and KA plus
NP031112-injected animals shows a 40-
fold decrease in the number of microglial
cells 9 d after KA injection in the
NP031112 group (Fig. 4d).
Double immunofluorescence staining
of the rat hippocampus 9 d after injection
of KA revealed an induction of the TNF-
cytokine, both in astrocytes andmicroglial
cells (Fig. 4e), whereas the expression of
this cytokine was almost completely ab-
sent in the neuronal population. Injection
of KA in the presence of NP031112 signif-
icantly decreased TNF--positive staining
both in astrocytes and microglia.
Subsequently, in view of the in vitro re-
sults described above, which suggested an
implication of the nuclear receptor
PPAR in the action of NP031112, we
next examined the possible involvement
of this receptor on NP031112 actions in
vivo. To this end, some rats were injected
with the PPAR antagonist GW9662 to-
gether with KA and NP031112 and killed
24 h later for histological evaluation. As
expected, KA injection induced a substan-
tial loss of hippocampal CA3 neurons and,
once more, NP031112 treatment afforded
robust neuroprotection (Fig. 5a,c). The
PPAR antagonist GW9662 alone did not
modify the number of surviving neurons
in vehicle-injected rats but abrogated
NP031112-elicited neuroprotection.
These findings suggest that NP031112 acts
via activation of PPAR to elicit protec-
tion of hippocampal neurons. Treatment
of rats with GW9662 also inhibited the
blocking effects of NP031112 on activa-
tion of microglia in the hippocampus, as
shown in Figure 5, b and d. Overall, these
findings indicate that NP031112 acts via
PPAR to protect hippocampal neurons
from KA-induced cell death and inflam-
mation. Next, we analyzed the neuropro-
tective effect of theGSK-3 inhibitor LiCl.
For this purpose, two additional groups of
rats were injected either with KA or with
KA plus LiCl, and the number of CA3 neurons and activated
microglial cells were determined in the hippocampus 24 h later.
As expected, LiCl alone does not alter any of the parameters
analyzed (data not shown). In contrast, LiCl administration
caused a moderate neuroprotective effect against KA-induced
injury (Fig. 5a,c) that was much lower than the one observed in
NP031112-treated animals. Correspondingly, the number of
OX-42-positive cells was slightly reduced in animals treated with
LiCl, compared with the KA-injected group (Fig. 5b,d). These
data further suggest that the effects of NP031112 are mediated
mainly throughPPAR activation, although some effects because
of its inhibition of GSK-3 cannot be discarded.
Figure 3. Neuroprotective effects of NP031112 on KA-induced excitotoxicity. a, Rats were injected with saline, KA, or KA plus
NP031112 and killed at different times after injection. Neuronal cell losswas assessed in coronal brain sections, using a Nissl stain.
Arrows indicate the injection site. Insets, 400magnifications of Nissl-stained CA3 cells (boxed areas). No apparent cell loss was
observed in control animals. Three days after KA, cell loss was apparent on the CA3 and CA1 subfields of the hippocampus in both
KA and KA plus NP031112-injected rats. By day 9, cell loss was more prominent in KA-injected animals, whereas animals treated
with NP031112 showed no cell loss. V, Vehicle; NP, NP031112.b, The extent of neuronal damage in the CA3 area of the hippocam-
pus was quantified as described in Materials and Methods. Data were normalized against the mean values given by vehicle-
injected rats. Values represent themean SD from five different animals and five independent sections per animal. **p 0.01;
***p 0.001, versus vehicle-injected animals at each time point.
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Susceptibility of NP031112-treated rats to
KA-induced seizures
KA administered intraperitoneally at a dose of 10 mg/kg caused
the entrance in SE in 80% of rats (Fig. 6a). Intragastrical admin-
istration of NP031112 1 h before KA injection had no effect on
the percentage of rats reaching SE (80%), and only a small delay
in the entrance of SE could be observed [126  8.9 min in the
NP031112-treated rats, comparedwith 104 5.5min ( p	 0.01)
in the control animals]. During the latency period, KA-injected
rats displayed approximately the same number of WDS than
NP031112-treated rats (Fig. 6b). We next evaluated neuronal
damage in coronal brain sections of surviving rats 72 h after KA
administration (Fig. 6c). Low-power images of the Nissl-stained
hippocampus revealed extensive damage, evident in the CA1 and
CA3 regions, whichwas substantially attenuated by orally admin-
istered NP031112. Together, these results suggest that the neuro-
protective effects of NP031112 cannot be attributed to an anti-
convulsant action.
Discussion
Collectively, our data clearly show that administration of the
TDZD NP031112 in a rat model of excitotoxicity markedly in-
duces neuroprotection and attenuates the production of proin-
flammatory cytokines and activation of astrocytes andmicroglial
cells. Additionally, NP031112 actions appear to be mediated
mainly through activation of the nuclear receptor PPAR within
the hippocampal cells, although part of its effects could be attrib-
utable to its inhibitory action of GSK-3 activity, because amod-
est neuroprotective effect of LiCl was observed in vivo. These
results suggest that NP031112 can be a therapeutic agent in neu-
Figure 4. Effect of NP031112 administration on KA-induced glial activation. a–d, GFAP- and OX-42-positive cells in the hippocampus. Rats were injected with saline, KA, or KA plus NP031112
and killed 9 d after injection. Arrows indicate the injection site. Coronal sections (30m) were stained with mouse monoclonal antibodies directed against either GFAP (a) or cd11b (OX-42; c) to
detect astrocytes or microglial cells, respectively, as described in Materials and Methods. Insets, 400magnifications of GFAP- and OX-42-stained cells (boxed regions). A significant increase in
gliosis is observed after KA injection, which is prevented in the animals treated with NP031112. b, Quantification of the number of reactive astrocytes and their mean immunostaining intensity
evaluated in themolecular layer of the hippocampus. Values represent themean SD from five different animals and five independent sections per animal. ***p 0.001. d, Quantification of the
number of reactive microglial cells analyzed in the molecular layer of the hippocampus. Values represent the mean SD from five different animals and five independent sections per animal.
***p 0.001. e, Induction of TNF- in astrocytes, microglia, and neurons after KA injection is abrogated by NP031112. Coronal sections were double stained with a polyclonal antibody directed
against TNF- andwithmousemonoclonal antibodies directed against NeuN, GFAP, or cd11b (OX-42) and examined by confocal microscopy. Photomicrographs showing representative CA3 fields
for each group are shown. Scale bars, 10m. DAPI was used as a counterstain.
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rodegenerative disorders inwhich excitotoxic neuronal cell death
and inflammation processes are involved.
We initially analyzed the anti-inflammatory andneuroprotec-
tive effects of NP031112 in an in vitro model of excitotoxicity,
using primary cultures of astrocytes, microglia, and neurons. We
show that NP031112 attenuates glutamate-induced excitotoxic
glial activation and neuronal damage. NP031112 appears to be an
extremely potent agent, because its effects were achieved at much
lower concentrations than the two other TDZD compounds pre-
viously examined (Luna-Medina et al., 2005). The mechanism of
action of all of these TDZD compounds in the neuroprotection
experiments in vitro seems to be the activation of the nuclear
receptor PPAR, as suggested by the activation of a reporter gene
containing a PPAR response element and the blocking effect of
the PPAR antagonist GW9662 of their anti-inflammatory and
neuroprotective actions. Although the TDZD compounds have
been identified previously as ATP-noncompetitive inhibitors of
GSK-3 activity (Martinez et al., 2002a,b), and it has been shown
that inactivation of GSK-3 protects against KA-induced neuro-
toxicity in vivo (Goodenough et al., 2004), it is unlikely that a
direct inhibition of this enzyme by TDZDs represents the major
mechanism for their anti-inflammatory and neuroprotective ef-
fects in vitro, because these effects were not entirely mimicked by
LiCl, a selective inhibitor of GSK-3 activity.
In the present study, we focused on the study of the anti-
inflammatory and neuroprotective effects of NP031112, in an in
vivo experimentalmodel of excitotoxicity. Excitotoxicity is a con-
cept of neuronal cell death caused by overactivation of excitatory
Figure 5. The PPAR antagonist GW9662 abolishes NP031112 neuroprotection after KA injection. Rats were injected with saline (V), KA, KA plus NP031112 (NP), or KA plus LiCl and killed 24 h
after injection. Someanimalswerealso injectedwith0.7gGW9662 (GW).Arrows indicate the injection site.a, Neuronal cell losswasassessed in coronal brain sectionsusingaNissl stain.NP031112
treatment affords robust neuroprotection in the CA3 regions of the hippocampus 24 h after KA injection, whereas LiCl administration only had a small effect on the decrease in CA3 neurons elicited
by KA injection. Injection of the PPAR antagonist GW9662 after NP031112 and KA treatment abolished this neuroprotection. Treatment with the PPAR antagonist did not affect the number of
surviving neurons in any of the other treatment groups. b, Gliosis was assessed in similar brain sections by staining with a mouse monoclonal antibody directed against cd11b (OX-42) to detect
microglial cells. Treatment with GW9662 blocked the anti-inflammatory effect of NP031112. c, Quantification of neuronal damage in the CA3 area of the hippocampus. d, Quantification of the
number of reactive microglial cells analyzed in the molecular layer of the hippocampus. Values represent the mean SD from five different animals and five independent sections per animal.
***p 0.001 versus vehicle-injected animals; #p 0.05; ##p 0.01; ###p 0.001 versus KA-injected animals.
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amino-acid receptors and it is thought to
represent a common biochemical path-
way, which plays an important role in the
pathogenesis of many acute and chronic
neurodegenerative disorders such as
stroke, traumatic brain injury, amyotro-
phic lateral sclerosis, and Parkinson’s,
Huntington’s, and Alzheimer’s diseases
(Dirnagl et al., 1999; Doble, 1999; Nico-
tera et al., 1999). Also, and as pointed out
in the Introduction, one of the events as-
sociated tomany brain neurodegenerative
diseases is an inflammation response,
which has long been linked to neuronal
cell death (Barone and Feuerstein, 1999;
del Zoppo et al., 2000). Inhibition of this
process could then protect against neuro-
degeneration and expansion of brain in-
jury. This view is further supported by ep-
idemiological data showing that long-
term treatment with NSAIDs may protect
against Alzheimer’s and Parkinson’s dis-
eases (Chen et al., 2003; Hald and Lo-
tharius, 2005; Townsend and Pratico,
2005).
Here, we show that NP031112 has a
potent anti-inflammatory effect in vivo af-
ter KA-induced excitotoxicity. In theMRI
studies, we analyzed the effect of
NP031112 on the inflammatory process
induced by KA at different times after in-
jection. NP031112 treatment reduced the
extension and intensity of the inflamma-
tion in the hippocampus and completely
abrogated the reduction in NAA, which
has been widely used as an indicator of
brain pathology and of disease progression (Demougeot et al.,
2004). NP031112 also reduced the increase in lactate observed in
the KA-injected animals. Increases of lactate concentration are
often related to pathologies, which enhance the anaerobic path-
way (Choi et al., 2005; Moller et al., 2005; Williams et al., 2005).
In agreement with these findings, our results also demonstrate
that NP031112 significantly reduces other inflammatory param-
eters, such as the accumulation of reactive astrocytes and micro-
glia in the hippocampus. The underlying mechanisms of this
anti-inflammatory effect of NP031112 may involve the suppres-
sion of certain cytokines [e.g., TNF-, because it has been shown
that the production of this cytokine can predispose to local in-
flammation and contribute to brain injury initiation and pro-
gression (Chao et al., 1995; Rizzi et al., 2003)]. Indeed, our results
show that administration of NP031112 significantly decreased
TNF- levels in vitro and in astrocytes andmicroglial cells in vivo
after KA injection. Together, these data clearly indicate that
NP031112 plays an important role in neuroinflammation and it
is able to efficiently block this process when locally injected at
very low concentrations in the damaged hippocampus.
In addition to this potent anti-inflammatory action of
NP031112, the administration of this compound also causes a
significant delay of neuronal cell loss in the CA1 and CA3 subre-
gions of the hippocampus. Twenty-four hours after intrahip-
pocampal injection, KA causes a prominent decrease in the num-
ber of neurons in the CA3 field of the hippocampus, which is
blocked by NP031112 administration (Fig. 3). These in vivo data,
together with the observed neuroprotective action in vitro against
glutamate-induced neurotoxicity, suggest that, in addition to its
anti-inflammatory effects, NP031112 could exert a more direct
neuroprotective action. Notably, 9 d after NP031112 injection,
both areas of the hippocampus were almost completely recov-
ered. As expected, intraperitoneal injection of KA induced typical
behavioral activity and histopathological changes in the hip-
pocampus (loss of pyramidal cells in CA1 and CA3 areas).
NP031112 acute administration had no effect on the behavioral
seizures; however, it inhibited hippocampal damage, suggesting
that the neuroprotective effects of this compound are not exerted
through an inhibition of seizure activity.
Regarding the molecular mechanisms underlying the effects
of NP031112, the present data are consistent with PPAR playing
a major role on its action. Our results demonstrate that
NP031112 is able to strongly activate a consensus PPAR re-
sponse element in primary astrocytes in culture and that blocking
this activation with a known PPAR antagonist results in a pre-
vention of theNP031112 neuroprotective effects in vitro aswell as
in vivo. These results, together with the in vitro and in vivo exper-
iments using the GSK-3 inhibitor LiCl, suggest that, although
TDZDs were originally identified as GSK-3 inhibitors, the
mechanisms by which NP031112 exerts its neuroprotective and
anti-inflammatory effects in excitotoxic injury involvemainly the
activation of the nuclear receptor PPAR. In agreement with
these results, an anti-inflammatory and neuroprotective effect
has been suggested for other PPAR agonists (for review, see
Figure 6. Effect of NP031112 administered orally on behavioral activity and neuronal loss after injection of KA.a,b, NP031112
(50mg/kg)was administered intragastrically 1hbefore intraperitoneal injectionof KA (10mg/kg), and thebehavioral activitywas
analyzed. NP031112 has no significant effects on behavioral seizures induced by KA. Each value represents themean SEM from
at least nine animals. c, The data correspond to animals that entered SE. Animalswere treated as ina, and 72 h after KA injections,
animalswere killed and coronal hippocampal sectionswere stainedwith Nissl. NP031112-treated rats exhibited a diminished loss
of neurons in the CA1 and CA3 regions, when compared with KA-injected rats. V, Vehicle; NP, NP031112. Values represent the
mean SD from five different animals and five independent sections per animal. ***p 0.001 versus vehicle-injected animals.
5774 • J. Neurosci., May 23, 2007 • 27(21):5766–5776 Luna-Medina et al. • Role of the TDZD NP031112 in Brain Injury
Landreth and Heneka, 2001; Townsend and Pratico, 2005).
Epidemiological studies have shown that the long-term use of
NSAIDs reduces the risk of developing and delays the onset of
both Alzheimer’s and Parkinson’s diseases (Chen et al., 2003).
Ibuprofen, an NSAID, reduces microglial activation induced
by -amyloid peptide (Combs et al., 2000) and amyloid
plaque load in an animal model of Alzheimer’s disease (Yan et
al., 2003). PPAR agonists of the TZD family, including ros-
iglitazone, pioglitazone, and troglitazone, have also been
shown to have anti-inflammatory and neuroprotective effects
(Diab et al., 2002; Camacho et al., 2004; Kiaei et al., 2005).
Additionally, 15-deoxy-- 12,14-prostaglandin J2, the most po-
tent natural ligand of PPAR, reduces in vitro microglial acti-
vation (Bernardo et al., 2000) and T cell activity in an animal
model of human multiple sclerosis (Diab et al., 2002). More
recently, a protective role of PPAR agonists against ischemic
brain injury has been demonstrated (Shimazu et al., 2005;
Sundararajan et al., 2005; Zhao et al., 2006).
In conclusion, we show that one single intrahippocampal in-
jection of the TDZD compound NP031112 affords robust neu-
roprotection of hippocampal neurons against excitotoxic injury
in adult rats. Our findings also suggest that the nuclear receptor
PPAR participates in this NP031112-induced neuroprotection.
Hence, NP031112 may hold promise for preventing permanent
neurological impairment in adults after a brain injury.
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